Statement 6: patients who are unresponsive to GH therapy should be given a trial of IGF-I.
Hardin
Dana S
DS
Division of Endocrinology, Metabolism & Diabetes, Department of Pediatrics, Columbus Children's Hospital, Ohio State University, Columbus, Ohio, USA.
D002648:Child; D004351:Drug Resistance; D019317:Evidence-Based Medicine; D019382:Human Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000627:therapeutic use*; D046150:Laron Syndrome / Q000188:drug therapy*
D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I